Susan C. Scott, MD, on EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib

September 15, 2025 By The ASCO Post Staff

Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the EGFR TKI lazertinib orally, resulted in high objective response rates among patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract MA08.05). 

Related Content